120
Participants
Start Date
April 15, 2022
Primary Completion Date
May 1, 2025
Study Completion Date
May 1, 2027
Anti-hypertensive agent: amlodipine
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Anti-hypertensive agent: Chlorthalidone
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Anti-hypertensive agent: Losartan
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Home BP monitoring with cuffed device
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
Home BP monitoring with cuffed device + BP patch
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
Home BP monitoring with cuffed device + BP watch
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
University of California San Francisco, San Francisco
University of California, San Francisco
OTHER